Integral Molecular, a biotechnology company, has announced the issuance of a new patent and patent family by the United States Patent and Trademark Office (USPTO) covering the composition of matter for its Lipoparticle technology.
This represents the third issued patent family, extending the company's patent landscape for key Lipoparticle technology.
Lipoparticles represent the company's proprietary technology that feature highly-concentrated membrane proteins in their native conformation for drug and antibody discovery against high-value targets including G protein-coupled receptors (GPCRs), ion channels, and transporters.
The company is the exclusive global patent holder or licensee of all Lipoparticle patents.
Integral Molecular is the only provider of licensed Lipoparticle technology.
Additional patents covering Lipoparticle technology are pending.
Integral Molecular president Dr Benjamin Doranz noted complex membrane proteins are exceptionally difficult to study, and there are currently no US Food and Drug Administration approved antibody therapeutics against high-value targets such as GPCRs, ion channels and transporters.
"Lipoparticles have become an established route for membrane protein antibody discovery, and our growing patent landscape strengthens our commitment to the discovery of these therapeutically important antibodies," Dr Doranz added.
The company provides custom Lipoparticles produced with user-specified target membrane proteins on a fee-for-service basis, and also provides ReadyReceptor Lipoparticles.
ReadyReceptor Lipoparticles contain pre-validated, high-concentration membrane protein targets.
Every lot of Lipoparticles is provided with technical protocols for relevant applications that include antibody generation and screening, biosensor assays, and enzyme-linked immunosorbent assay binding assays.
To accommodate specialized applications, these Lipoparticles can be biotinylated or fluorescently labeled.